Third-Line Approach: 54-Year-Old Patient Treated With Tucatinib-Based Regimen

Opinion
Video

Panelists discuss how a third-line approach for a 54-year-old patient treated with a tucatinib-based regimen involves careful consideration of prior treatment responses, comorbidities, and the potential benefits of combining tucatinib with capecitabine and trastuzumab to improve outcomes in HER2+ metastatic breast cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Related Content